Literature DB >> 31073439

Intravenous Immunoglobulin Therapy for Cerebral Vasculitis Associated with Rocky Mountain Spotted Fever.

H Christine Allen1, Robert C Welliver2, Monica W Fogarty3, Morris Gessouroun1, Emilie D Henry1.   

Abstract

Rocky Mountain spotted fever is a tick-borne illness that is prevalent in the south and the central United States, primarily during the summer months. Patients with delayed diagnosis can experience increased mortality and morbidity, particularly poor neurological outcome. We present a case of a 7-year-old girl with Rocky Mountain spotted fever who was admitted with severe neurological changes and septic shock on day 8 of illness. She was initially diagnosed with Kawasaki disease and treated with intravenous immunoglobulin. Her treatment also included doxycycline, vancomycin, and ceftriaxone due to concerns regarding Rocky Mountain spotted fever and bacterial sepsis. During hospitalization, the patient required mechanical ventilation for respiratory distress, inotropic support, and fluid resuscitation for hypotension. Titers for Rocky Mountain spotted fever were ultimately positive, with magnetic resonance imaging of the brain demonstrating numerous punctate foci of restricted diffusion within the supratentorium, including the corpus callosum and basal ganglia. Although the patient presented late in the disease course, she ultimately had a good neurological outcome. We theorized that administration of intravenous immunoglobulin prevented ongoing neurological injuries from the cerebral vasculitis, which are associated with Rocky Mountain spotted fever.

Entities:  

Keywords:  Rocky Mountain spotted fever; cerebral vasculitis; intravenous immunoglobulin; septic shock

Year:  2016        PMID: 31073439      PMCID: PMC6260288          DOI: 10.1055/s-0036-1587327

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  9 in total

Review 1.  What's new in Rocky Mountain spotted fever?

Authors:  Luke F Chen; Daniel J Sexton
Journal:  Infect Dis Clin North Am       Date:  2008-09       Impact factor: 5.982

Review 2.  Rocky Mountain spotted fever: 'starry sky' appearance with diffusion-weighted imaging in a child.

Authors:  Seth Crapp; Dana Harrar; Megan Strother; Curtis Wushensky; Sumit Pruthi
Journal:  Pediatr Radiol       Date:  2011-09-01

3.  Clinical profile and predictors of fatal Rocky Mountain spotted fever in children from Sonora, Mexico.

Authors:  Gerardo Alvarez-Hernandez; Coral Murillo-Benitez; Maria del Carmen Candia-Plata; Manuel Moro
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

4.  Ongoing Cerebral Vasculitis During Treatment of Rocky Mountain Spotted Fever.

Authors:  Lisa R Sun; Thierry A G M Huisman; Anusha K Yeshokumar; Michael V Johnston
Journal:  Pediatr Neurol       Date:  2015-07-22       Impact factor: 3.372

5.  Fatal Rocky Mountain spotted fever in the United States, 1999-2007.

Authors:  F Scott Dahlgren; Robert C Holman; Christopher D Paddock; Laura S Callinan; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

6.  Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted fever in children.

Authors:  Steven C Buckingham; Gary S Marshall; Gordon E Schutze; Charles R Woods; Mary Anne Jackson; Lori E R Patterson; Richard F Jacobs
Journal:  J Pediatr       Date:  2007-02       Impact factor: 4.406

7.  Therapeutic delay and mortality in cases of Rocky Mountain spotted fever.

Authors:  K B Kirkland; W E Wilkinson; D J Sexton
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

Review 8.  An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes.

Authors:  Deane Yim; Nigel Curtis; Michael Cheung; David Burgner
Journal:  J Paediatr Child Health       Date:  2013-05-07       Impact factor: 1.954

9.  Kawasaki disease following Rocky Mountain spotted fever: a case report.

Authors:  Aswine K Bal; Steven W Kairys
Journal:  J Med Case Rep       Date:  2009-07-06
  9 in total
  1 in total

1.  Impact of a Severe Rocky Mountain Spotted Fever Case on Treatment Practices at an Academic Institution Within a Nonendemic Area.

Authors:  Conrad Krawiec; Gary D Ceneviva; Shouhao Zhou; Neal J Thomas
Journal:  Wilderness Environ Med       Date:  2021-08-12       Impact factor: 1.518

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.